Overview

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer

Status:
Terminated
Trial end date:
2017-05-22
Target enrollment:
Participant gender:
Summary
This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining varlilumab and atezolizumab. Phase l of the study will enroll patients with a number of tumor types; Phase ll will enroll only patients with renal cell carcinoma (RCC).* *Note: This Study was terminated prior to initiation of Phase II
Phase:
Phase 1
Details
Lead Sponsor:
Celldex Therapeutics
Collaborator:
Genentech, Inc.
Treatments:
Antibodies, Monoclonal
Atezolizumab